(Q38131058)

English

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

scientific article published on 24 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 August 2017

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me (English)

1 reference

Europe PubMed Central

29 August 2017

0 references

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

Michael Hutchinson

object named as

Michael Hutchinson

2

0 references

object named as

Eva Havrdova

1

0 references

7

object named as

Ralf Gold

1 reference

Europe PubMed Central

29 August 2017

author name string

Nuwan C Kurukulasuriya

3

1 reference

Europe PubMed Central

29 August 2017

Kartik Raghupathi

4

1 reference

Europe PubMed Central

29 August 2017

Marianne T Sweetser

5

1 reference

Europe PubMed Central

29 August 2017

Katherine T Dawson

6

1 reference

Europe PubMed Central

29 August 2017

language of work or name

0 references

publication date

24 August 2013

1 reference

Europe PubMed Central

29 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

29 August 2017

14

1 reference

Europe PubMed Central

29 August 2017

15

1 reference

Europe PubMed Central

29 August 2017

2145-2156

1 reference

Europe PubMed Central

29 August 2017

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Cost of multiple sclerosis in the Czech Republic: the COMS study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Cost of managing an episode of relapse in multiple sclerosis in the United States

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

SF-36 health survey update

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Health-related quality of life in multiple sclerosis: effects of natalizumab

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Emerging treatments in multiple sclerosis: azathioprine and mofetil

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.826190

21 January 2018

Identifiers

10.1517/14656566.2013.826190

1 reference

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38131058&oldid=1525070432"